Correction: Real‑world experience with calcitonin gene‑related peptide‑targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers

Correction: BMC Neurol 24, 32 (2024)

https://doi.org/10.1186/s12883-023-03521-y

Following publication of the original article [1], the authors would like to correct a couple of errors in numerical data under the headings “Effects of CGRP mAbs on MMDs”, “Comparison of the therapeutic effects on MMDs among CGRP mAbs” and Table 1.

Effects of CGRP mAbs on MMDs.

The sentence currently reads:

Significant MMD reductions from baseline to V3 were observed in both EM (9.0 ± 7.3 vs. 19.1 ± 6,1, p = 0.0001, Supplementary Fig. 1A) and CM (7.1 ± 4.5 vs. 11.2 ± 4.2, p < 0.0001, Supplementary Fig. 1B).

The sentence should read:

Significant MMD reductions from baseline to V3 were observed in both CM (9.0 ± 6.0 vs. 19.1 ± 6,1, p = 0.0001, Supplementary Fig. 1A) and EM (6.8 ± 5.2 vs. 11.2 ± 4.2, p < 0.0001, Supplementary Fig. 1B).

Comparison of the therapeutic effects on MMDs among CGRP mAbs.

The sentence currently reads:

As shown in Fig. 5A–C, galcanezumab and fremanezumab significantly reduced MMDs after 3 doses (galcanezumab: 7.1 ± 5.8 vs. 14.0 ± 5.9, p = 0.0001; fremanezumab: 7.8 ± 5.4 vs. 19.1 ± 5.5, p = 0.0042),…

The sentence should read:

As shown in Fig. 5A–C, galcanezumab and fremanezumab significantly reduced MMDs after 3 doses (galcanezumab: 7.1 ± 5.8 vs. 14.0 ± 5.9, p = 0.0001; fremanezumab: 7.8 ± 5.4 vs. 12.1 ± 5.5, p = 0.0042),….

In Table 1 under column Fremanezumab, 67.2 ± 2 5.5 should be changed to 67.2 ± 5.5.

The original article [1] has been updated.